Catalent today announced that it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for $44.5 million.
The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.
Catalent today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
Catalent today announced the completion of a $30 million project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
NurOwn is BrainStorm’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (PMS) and other neurodegenerative diseases.
Catalent today announced a $230 million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland, to meet growing customer demand.
